Longevity
Thymosin Alpha-1
Thymosin Alpha-1 (Tα1)
Evidence tier: Approved in 35+ countries (not FDA). Human RCT data for hepatitis B/C, cancer adjunct, sepsis.
| Molecular weight | 3108.4 Da |
| Molecular formula | C129H215N33O55 |
| CAS number | 62304-98-7 |
| Half-life | ~2 hours |
| Administration | subcutaneous |
| Research dose | 1.6 mg twice weekly (approved dosing); some protocols use higher doses |
Amino Acid Sequence
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
Primary Mechanism
TLR signalling modulation, T-cell maturation, dendritic cell activation, NK cell activity
Studied For
immune restorationchronic infectioncancer immunotherapy adjunctsepsisthymic ageing
Reconstitution
Reconstitute with bacteriostatic water. For a 1.5 mg vial add 1 mL BW.
Storage
Lyophilised: store at -20°C. Reconstituted: refrigerate, use within 48 hours.
Notes
Approved as Zadaxin in Asia, Eastern Europe, and South America. Khavinson longevity research shows significant mortality reduction in elderly over multi-year protocols. Not the same as Thymosin Beta-4 / TB-500.
This page contains affiliate links. If you purchase through these links, I may earn a commission at no extra cost to you.
These products are sold for research purposes only and are not intended for human consumption.